Diabetes treatment by conversion of gut epithelial cells to insulin-producing cells.
autoimmunity
diabetes
intestine
Journal
Journal of diabetes investigation
ISSN: 2040-1124
Titre abrégé: J Diabetes Investig
Pays: Japan
ID NLM: 101520702
Informations de publication
Date de publication:
01 Mar 2024
01 Mar 2024
Historique:
received:
01
02
2024
accepted:
15
02
2024
medline:
1
3
2024
pubmed:
1
3
2024
entrez:
1
3
2024
Statut:
aheadofprint
Résumé
Insulin-deficient (type 1) diabetes is treated by providing insulin to maintain euglycemia. The current standard of care is a quasi-closed loop integrating automated insulin delivery with a continuous glucose monitoring sensor. Cell replacement technologies are advancing as an alternative treatment and have been tested as surrogates to cadaveric islets in transplants. In addition, immunomodulatory treatments to delay the onset of type 1 diabetes in high-risk (stage 2) individuals have gained regulatory approval. We have pioneered a cell conversion approach to restore insulin production through pharmacological conversion of intestinal epithelial cells into insulin-producing cells. We have advanced this approach along a translational trajectory through the discovery of small molecule forkhead box protein O1 inhibitors. When administered to different rodent models of insulin-deficient diabetes, these inhibitors have resulted in robust glucose-lowering responses and generation of insulin-producing cells in the gut epithelium. We review past work and delineate a path to human clinical trials.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIH HHS
ID : DK57539
Pays : United States
Organisme : NIH HHS
ID : DK58282
Pays : United States
Organisme : NIH HHS
ID : DK64819
Pays : United States
Organisme : NIH HHS
ID : DK63609
Pays : United States
Informations de copyright
© 2024 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd.
Références
Atkinson MA, Bluestone JA, Eisenbarth GS, et al. How does type 1 diabetes develop?: The notion of homicide or beta-cell suicide revisited. Diabetes 2011; 60: 1370-1379.
IDF. IDF Diabetes Atlas, 10th edn. Brussels, Belgium: International Diabetes Federation, 2021.
Hughes MS, Addala A, Buckingham B. Digital Technology for Diabetes. N Engl J Med 2023; 389: 2076-2086.
Chatenoud L, Thervet E, Primo J, et al. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci USA 1994; 91: 123-127.
Herold KC, Bundy BN, Long SA, et al. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N Engl J Med 2019; 381: 603-613.
Jacobsen L, Bundy B, Greco M, et al. Comparing beta cell preservation across clinical trials in recent-onset type 1 diabetes. Diabetes Technol Ther 2020; 22: 948-953.
Quattrin T, Haller MJ, Steck AK, et al. Golimumab and Beta-cell function in youth with new-onset type 1 diabetes. N Engl J Med 2020; 383: 2007-2017.
Waibel M, Wentworth JM, So M, et al. Baricitinib and beta-cell function in patients with new-onset type 1 diabetes. N Engl J Med 2023; 389: 2140-2150.
Herold KC, Gitelman SE, Gottlieb PA, et al. Teplizumab: A disease-modifying therapy for type 1 diabetes that preserves beta-cell function. Diabetes Care 2023; 46: 1848-1856.
Ziegler AG, Kick K, Bonifacio E, et al. Yield of a public health screening of children for islet autoantibodies in Bavaria, Germany. JAMA 2020; 323: 339-351.
Helman A, Melton DA. A stem cell approach to cure type 1 diabetes. Cold Spring Harb Perspect Biol 2020; 13: a035741.
Ramzy A, Thompson DM, Ward-Hartstonge KA, et al. Implanted pluripotent stem-cell-derived pancreatic endoderm cells secrete glucose-responsive C-peptide in patients with type 1 diabetes. Cell Stem Cell 2021; 28: 2047-2061 e5.
Shapiro AMJ, Thompson D, Donner TW, et al. Insulin expression and C-peptide in type 1 diabetes subjects implanted with stem cell-derived pancreatic endoderm cells in an encapsulation device. Cell Rep Med 2021; 2: 100466.
McKimpson WM, Accili D. Reprogramming cells to make insulin. J Endocr Soc 2019; 3: 1214-1226.
Cheung AT, Dayanandan B, Lewis JT, et al. Glucose-dependent insulin release from genetically engineered K cells. Science 2000; 290: 1959-1962.
Yang K, O'Cearbhaill ED, Liu SS, et al. A therapeutic convection-enhanced macroencapsulation device for enhancing beta cell viability and insulin secretion. Proc Natl Acad Sci USA 2021; 118: e2101258118.
Schonhoff SE, Giel-Moloney M, Leiter AB. Neurogenin 3-expressing progenitor cells in the gastrointestinal tract differentiate into both endocrine and non-endocrine cell types. Dev Biol 2004; 270: 443-454.
Bany Bakar R, Reimann F, Gribble FM. The intestine as an endocrine organ and the role of gut hormones in metabolic regulation. Nat Rev Gastroenterol Hepatol 2023; 20: 784-796.
Haeusler RA, McGraw TE, Accili D. Biochemical and cellular properties of insulin receptor signalling. Nat Rev Mol Cell Biol 2018; 19: 31-44.
Nakae J, Kitamura T, Kitamura Y, et al. The forkhead transcription factor Foxo1 regulates adipocyte differentiation. Dev Cell 2003; 4: 119-129.
Kitamura T, Kitamura YI, Funahashi Y, et al. A Foxo/notch pathway controls myogenic differentiation and fiber type specification. J Clin Invest 2007; 117: 2477-2485.
Kitamura T, Kitamura YI, Kobayashi M, et al. Regulation of pancreatic juxtaductal endocrine cell formation by FoxO1. Mol Cell Biol 2009; 29: 4417-4430.
Talchai C, Xuan S, Kitamura T, et al. Generation of functional insulin-producing cells in the gut by Foxo1 ablation. Nat Genet 2012; 44: 406-412, S1.
Bouchi R, Foo KS, Hua H, et al. FOXO1 inhibition yields functional insulin-producing cells in human gut organoid cultures. Nat Commun 2014; 5: 4242.
Kitamoto T, Lee YK, Sultana N, et al. Chemical induction of gut beta-like-cells by combined FoxO1/notch inhibition as a glucose-lowering treatment for diabetes. Mol Metab 2022; 66: 101624.
Chen YJ, Finkbeiner SR, Weinblatt D, et al. De novo formation of insulin-producing "neo-beta cell islets" from intestinal crypts. Cell Rep 2014; 6: 1046-1058.
Ariyachet C, Tovaglieri A, Xiang G, et al. Reprogrammed stomach tissue as a renewable source of functional β cells for blood glucose regulation. Cell Stem Cell 2016; 18: 410-421.
Zhou Q, Brown J, Kanarek A, et al. In vivo reprogramming of adult pancreatic exocrine cells to β-cells. Nature 2008; 455: 627-632.
Kim H, Toyofuku Y, Lynn FC, et al. Serotonin regulates pancreatic beta cell mass during pregnancy. Nat Med 2010; 16: 804-808.
Ohara-Imaizumi M, Kim H, Yoshida M, et al. Serotonin regulates glucose-stimulated insulin secretion from pancreatic beta cells during pregnancy. Proc Natl Acad Sci USA 2013; 110: 19420-19425.
Du W, Wang J, Kuo T, et al. Pharmacological conversion of gut epithelial cells into insulin-producing cells lowers glycemia in diabetic animals. J Clin Invest 2022; 132: e162720.
Egozi A, Llivichuzhca-Loja D, McCourt BT, et al. Insulin is expressed by enteroendocrine cells during human fetal development. Nat Med 2021; 27: 2104-2107.
Veres A, Faust AL, Bushnell HL, et al. Charting cellular identity during human in vitro beta-cell differentiation. Nature 2019; 569: 368-373.
Langlet F, Haeusler RA, Linden D, et al. Selective inhibition of FOXO1 activator/repressor balance modulates hepatic glucose handling. Cell 2017; 171: 824-835 e18.
Belvedere S, Lin HV, Devita RJ, et al. FORKHEAD BIOTHERAPEUTICS INC (FORK-Non-standard) FORKHEAD BIOTHERAPEUTICS INC (FORK-Non-standard) FORKHEAD BIOTHERAPEUTICS INC (FORK-Non-standard) FORKHEAD BIOTHERAPEUTICS INC (FORK-Non-standard), assignee. New heterocyclic compounds are forkhead box protein O1 inhibitors used to treat e.g. diabetes, insulin-dependent diabetes, type 1 diabetes mellitus, type 2 diabetes, gestational diabetes, or diabetes secondary to pancreatectomy patent WO2022066938-A1; AU2021348064-A1; CA3190562-A1; EP4217355-A1; US2023416228-A1. WO2022066938-A1 31 Mar 2022 C07D-403/12 202238 Pages: 583 English AU2021348064-A1 23 Mar 2023 C07D-403/12 202325 English CA3190562-A1 31 Mar 2022 C07D-403/12 202328 English EP4217355-A1 02 Aug 2023 C07D-403/12 202363 English US2023416228-A1 28 Dec 2023 C07D-401/14 202402 English.
Tanaka H, Nagashima T, Shimaya A, et al. Effects of the novel Foxo1 inhibitor AS1708727 on plasma glucose and triglyceride levels in diabetic db/db mice. Eur J Pharmacol 2010; 645: 185-191.
Lee YK, Diaz B, Deroose M, et al. FOXO1 inhibition synergizes with FGF21 to normalize glucose control in diabetic mice. Mol metab 2021; 49: 101187.
Calissi G, Lam EW, Link W. Therapeutic strategies targeting FOXO transcription factors. Nat Rev Drug Discov 2021; 20: 21-38.
Paik JH, Kollipara R, Chu G, et al. FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell 2007; 128: 309-323.
Trinh DL, Scott DW, Morin RD, et al. Analysis of FOXO1 mutations in diffuse large B-cell lymphoma. Blood 2013; 121: 3666-3674.
Ng SWK, Rouhani FJ, Brunner SF, et al. Convergent somatic mutations in metabolism genes in chronic liver disease. Nature 2021; 598: 473-478.
Jang JY, Hwang I, Pan H, et al. A FOXO1-dependent transcription network is a targetable vulnerability of mantle cell lymphomas. J Clin Invest 2022; 132: e160767.
Kerdiles YM, Stone EL, Beisner DR, et al. Foxo transcription factors control regulatory T cell development and function. Immunity 2010; 33: 890-904.
Schumann K, Raju SS, Lauber M, et al. Functional CRISPR dissection of gene networks controlling human regulatory T cell identity. Nat Immunol 2020; 21: 1456-1466.
Kitamoto T, Kuo T, Okabe A, et al. An integrative transcriptional logic model of hepatic insulin resistance. Proc Natl Acad Sci USA 2021; 118: e2102222118.
Pajvani UB, Shawber CJ, Samuel VT, et al. Inhibition of notch signaling ameliorates insulin resistance in a FoxO1-dependent manner. Nat Med 2011; 17: 961-967.
Lee YK, Du W, Nie Y, et al. Single-agent FOXO1 inhibition normalizes glycemia and induces gut beta-like cells in streptozotocin-diabetic mice. Mol Metab 2022; 66: 101618.